SCHEMBL3976513

SCHEMBL3976513

CCOC(=O)c1occc1-c1cccc(NC(C)=O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.47
GAA P10253 1/20 0.47
CRHBP P24387 1/20 0.47
HTT P42858 1/20 0.47
CRHR2 Q13324 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
RAB9A P51151 5/20 0.46
NPC1 O15118 3/20 0.46
NQO2 P16083 2/20 0.45
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 2/20 0.44
BRD4 O60885 1/20 0.44
POLB P06746 1/20 0.44
NR4A1 P22736 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
HSD17B10 Q99714 1/20 0.43
TSHR P16473 3/20 0.43
MMP13 P45452 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3975993 0.86 RAB9A (0.54) GAARAB9ANPC1KMT2AMEN1
SCHEMBL3978715 0.84 MGLL (0.61) RAB9ANPC1SMN1; SMN2LMNAHSD17B10
SCHEMBL27624311 0.82 NQO2 (0.55) KDM4ERAB9ANPC1NQO2KMT2A
SCHEMBL3978197 0.81 ALDH1A1 (0.48) RAB9ANPC1NQO2SMN1; SMN2BRD4
SCHEMBL3977097 0.81 FNTA (0.46) KDM4EGAARAB9ANPC1KMT2A
SCHEMBL3976847 0.80 SMN1; SMN2 (0.53) KDM4EGAATDP1RAB9ANPC1
SCHEMBL3982536 0.79 TSHR (0.47) KDM4EGAARAB9ANPC1KMT2A
SCHEMBL3977084 0.77 ALDH1A1 (0.52) KDM4EGAACRHBPHTTCRHR2
SCHEMBL3978291 0.75 HPGD (0.39) KDM4EHTTRAB9ANPC1KMT2A
SCHEMBL7808621 0.74 SMN1; SMN2 (0.70) KDM4ERAB9ANPC1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 US disclosed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 US disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same GLP1R, GCGR, GPR119 KDM4E 2769/4885GAA 1023/4885CRHBP 1351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.